finmarketnews.com
news-details
Health,Watchlist,healthcare stocks

3 HealthTech Stocks Trending Now GOSS stock, LLY stock, SNYNF stock

Powered by healthtechmovers.com

According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist.  That staff here at finmarketnews.com, will continue to monitor these healthtech companies to see if the momentum continues. FinMarketNews.com is looking into these tickers DAWN, MTDR, AVY, CMC, MNST, RTX and more..

Gossamer Bio, GOSS
Recent GOSS Stock Price: $2.16
Summary:
Gossamer Bio Inc. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutics in the areas of immunology, inflammation and oncology. The company's product pipeline includes GB001, GB002, GB004, GB1275, Autoimmune program and Oncology program which are in clinical stage. Gossamer Bio Inc. is based in San Diego, California.

Paul Choi analyst at Goldman Sachs reiterates coverage on Gossamer Bio (GOSS) stock in the energy sector with a Buy rating and has set GOSS's stock price target at $ 10.

TipRanks.com reports that Gossamer Bio currently has n/a analysts offering 12-month price targets on GOSS and the consensus is a Moderate Buy rating with an average stock price target of n/a.  The most recent GOSS stock price we have is $2.16 and we are not making any GOSS forecasts at this time.

In addition, TradingView issued a Sell rating for GOSS over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on GOSS. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.

For the complete breakdown on GOSS, please click here >>

Eli Lilly & Co, LLY
Recent LLY Stock Price: $371.97
Summary:
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.

Seamus Fernandez analyst at Guggenheim reiterates coverage on Eli Lilly & Co (LLY) stock in the energy sector with a Buy rating and has set LLY's stock price target at $ 401.

TipRanks.com reports that Eli Lilly & Co currently has 15 analysts offering 12-month price targets on LLY and the consensus is a Strong Buy rating with an average stock price target of $387.93.  The most recent LLY stock price we have is $371.97 and we are not making any LLY forecasts at this time.

In addition, TradingView issued a Buy rating for LLY over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on LLY. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.

For the complete breakdown on LLY, please click here >>

Sanofi, SNYNF
Recent SNYNF Stock Price: $94.425
Summary:
Sanofi was incorporated under the laws of France in 1994 as a société anonyme, a form of limited liability company. It is a healthcare company, engaged in the research, development, manufacture and marketing of healthcare products. Its principal activities include Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. It also operates through the following platforms: Emerging Markets, Diabetes Solutions, Vaccines, Consumer Health Care (CHC), Animal Health, Genzyme, and Other Innovative Products. The Pharmaceuticals segment covers research, development, production and marketing of medicines, including activities acquired with Genzyme. Sanofi's pharmaceuticals portfolio consists of flagship products, plus prescription medicines, generic medicines, and consumer health products. This segment also includes all associates and joint ventures whose activities are related to pharmaceuticals, in particular the entities majority owned by BMS. The Vaccines segment is wholly dedicated to vaccines, including research, development, production and marketing. This segment includes Sanofi Pasteur MSD joint venture with Merck & Co., Inc. in Europe. The Animal Health segment comprises the research, development, production and marketing activities of Merial, which offers medicines and vaccines for a wide variety of animal species. Its competitors include Novo Nordisk, Merck, Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Shire, Pfizer, Biogen Idec, Teva and Merck Serono, Bayer, Roche, Johnson & Johnson, AstraZeneca, Boehringer-Ingelheim, Fresenius Medical Care, among others. The Company's products and manufacturing facilities are subject to significant government regulations and approvals.

Eric Le analyst at Stifel Nicolaus reiterates coverage on Sanofi (SNYNF) stock in the energy sector with a Buy rating and has set SNYNF's stock price target at $ 109.96.

TipRanks.com reports that Sanofi currently has 12 analysts offering 12-month price targets on SNYNF and the consensus is a Moderate Buy rating with an average stock price target of $108.57.  The most recent SNYNF stock price we have is $94.425 and we are not making any SNYNF forecasts at this time.

In addition, TradingView issued a Buy rating for SNYNF over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on SNYNF. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.

For the complete breakdown on SNYNF, please click here >>



The editors at finmarketnews.com use a variety of research tools to generate our watchlists and research reports.  One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals.  TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>

FinMarketNews.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to FinMarketNews.com.

Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.    
==============================================================================